Sentences with phrase «aids vaccine study»

The fog around the largest AIDS vaccine study ever conducted began to lift today, as Thai and U.S. researchers for the first time publicly presented a detailed analysis of their data to over 1000 scientists gathered here at an annual meeting.

The media's varied interpretations of the Thai AIDS vaccine study's results reflect the widespread confusion over the meaning of statistical significance.

«Results from a former AIDS vaccine study have shown that in a worst case scenario, immunization against HIV could enhance infection,» says Christiane Stahl - Hennig, who designed the project in cooperation with the former DPZ employee Sieghart Sopper.

Not exact matches

A new study has cast fresh doubts on an AIDS vaccine that was abandoned in 2007 because of fears that it made some recipients more susceptible to HIV infection.

Group C was composed of women with counts below 200, the defining level of AIDS for which response to an HPV vaccine had not yet been studied.

To address that debate, Kojic's study, dubbed «AIDS Clinical Trials Group Protocol 5240,» measured the safety and immune system response of the vaccine in HIV - positive women aged 13 to 45 with a wide range of immune statuses.

The study also provides key insights that could aid development of new vaccines.

Researchers led by a team at Duke University identified these immunologic variations by studying blood samples collected from people living with HIV by the NIAID - supported Center for HIV / AIDS Vaccine Immunology (CHAVI).

LONDON (Reuters)-- Researchers announced the launch of two big studies in Africa on Thursday to test a new HIV vaccine and a long - acting injectable drug, fuelling hopes for better ways to protect against the virus that causes AIDS.

Of more than 50 therapeutic vaccine trials so far, this is the first one that has bolstered the immune system in a «meaningful» way, says Steven Deeks, an HIV / AIDS clinician and researcher at the University of California, San Francisco, who is «cautiously optimistic» that the data will inspire others to study the approach.

In later life Salk went on to found the Salk Institute for Biological Studies in La Jolla, Calif., and in the mid-1980s he started working on an AIDS vaccine.

The work and other similar, recent studies could also help «redefine» how vaccines are developed to make them more effective and less likely to have side effects, says Wayne Koff, the chief scientific officer at the International AIDS Vaccine Initiative in New York City, who was not involved with the research.

SN: You're suggesting combining the two earlier AIDS vaccine efficacy studies that have been done?

«Currently, there is a lot of focus on the use of antibodies transferred passively or through a vaccine to prevent infection in infants, however this study cautions against that and suggests that broadly neutralizing antibodies may actually aid in enhancing transmission from mother to child,» added Sagar, an attending physician in infectious diseases at Boston Medical Center.

AIDS researcher Jay Levy at the University of California at San Francisco finds the results encouraging, but notes that the vaccines seemed to have no effect on the amount of virus in the bloodstream of people who contracted HIV during the study.

Batista was one of a number of scientists involved in the study from the Ragon Institute, established in the Boston area by experts from Massachusetts General Hospital, Harvard University and the Massachusetts Institute of Technology, with the goal of working toward development of an effective vaccine against HIV / AIDS.

While studying a group of women at risk of HIV in Mombasa, Kenya, Dr. Julie Overbaugh and colleagues found a potential vulnerability in the AIDS virus that could lead to clues for designing an effective vaccine.

Institutions public or private that believe they are compelled to communicate about a study prior to its presentation at AIDS Vaccine 2013, whether for reasons of disclosure of material data, notification of study participants, or any other reason must notify the Conference Secretariat and receive written approval prior to any public communication.

«The data from this study show the promise of vector - mediated gene transfer as an approach for immunization,» says Pat Fast, chief medical officer at the International AIDS Vaccine Initiative.

On September 13, 2011, COL Jerome Kim, MHRP, and Dr. Bart Haynes, Duke University, presented two plenary sessions at the AIDS Vaccine conference on the discovery work related to correlates studies on the RV144 trial.

Study results, presented at the 2009 AIDS Vaccine Conference, suggest that MVA - CMDR is an ideal candidate for future prime - boost vaccination strategies.

In 2006, a group of 613 people recently infected with HIV from Uganda, Rwanda, Zambia, Kenya, and South Africa volunteered for a scientific study group led by the International AIDS Vaccine Initiative (IAVI).

Among other things, it features articles on new developments in HIV cure research, recent studies that show promise but also possible pitfalls of using adenovirus vectors in HIV vaccine candidates, and the funding crisis at the Global Fund to Fight AIDS, Tuberculosis and Malaria.

Some of the children were in a second study, funded by legal aid, to investigate whether parents who claimed that their children were damaged by the MMR vaccine had grounds for a High Court compensation claim.

At the International AIDS Society conference in Paris, scientists announced that in an early - stage clinical trial, a new HIV vaccine regimen generated antibody responses in 100 percent of volunteers in most arms of the study.

IAVI launched the Neutralizing Antibody Consortium (NAC) in 2002 to study the molecular structure and biochemistry of known broadly neutralizing antibodies and to use this information to design (reverse engineer) potentially powerful AIDS vaccine candidates.